Insider trade

CEO sold ~$11M of MRNA shares in the open market

Traded Aug 5, 2026 · Filed Aug 7, 2026

ModernaMRNA

~$11M
Reported value · 187K sh @ $58.79: 6.19M
Holds after · shares reported: +235.9%
stock since the trade · S&P 500 -0.8%, $56.255 → $188.94 on Oct 1

Why it stands out

The boss of Moderna sold $11M of Moderna shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Aug 5, 2026
Reporting period: Not applicable
Filed with the SEC: Aug 7, 2026

CEO$1M+Pre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$10,996,317

Shares × reported transaction price

Timing vs results

5 days after results of Jul 31, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $56.255 on Aug 5, 2026, 152% above its 52-week low and 31% below its high, after an 8% drop over the previous 30 trading days

52-week range $22.36 (Nov 20, 2025) to $81.80 (Jul 6, 2026), 57% of the way up, from 251 adjusted closes. 30 trading days earlier: $61.00 on Jun 23, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Aug 9, 2024 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.

Wentz v. Moderna, Inc., docket 1:24-cv-12058, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	+7.8%	-0.1%	+7.8%
30 days	+126.7%	-1.4%	+128.1%

Past results only. Not a forecast.

Source receipt

Record ID: 0001682852-26-000153
Filed / recorded: Aug 7, 2026, 8:11 PM UTC
Added to OQRO: Oct 2, 2026, 12:28 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: Moderna, Inc.
Issuer CIK: 1682852
Ticker: MRNA
Reporting person: Stephane Bancel
Relationship: Director, Officer
Officer title: Chief Executive Officer
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Aug 5, 2026
Transaction code: S
Shares / units: 187,044
Price per share: $58.79
Acquired / disposed: Disposed (D)
Shares owned after: 6,187,791
Ownership form: Direct
Amendment: No

Footnotes from the filing

The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.61 to $59.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.